The FDA authorized Zyn nicotine pouches to be marketed as a lower-risk alternative to cigarettes.
The Food and Drug Administration (FDA) has officially authorized the marketing of Zyn nicotine pouches as a lower-risk alternative to traditional cigarettes. The administration announced that using Zyn instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Bret Koplow, acting director of the FDA's Center for Tobacco Products, stated the decision provides science-based information to help adult users make informed choices. While advocates like Mitch Zeller argue that the pouches are demonstrably less harmful than burning tobacco leaves, some researchers express caution. Bonnie Halpern-Felsher noted that while the products have harm reduction potential for current smokers, it is too soon to determine their long-term effects on oral cancer. Additionally, Dr. Robert Jackler warned that the marketing of flavored pouches may encourage youth use, which experts agree is not necessary for children. Emily Hilliard, a senior press secretary for the Department of Health and Human Services, emphasized that the FDA remains committed to preventing youth access and maintaining the federal minimum age of 21 for tobacco products.